CD86 and neoplasm: Enhanced expression of CD80/CD86 (44, 46, 47) and CCR7 (44); more efficient priming of tumor-specific CD8+ CTL responses (43, 46, 47) and Th1 responses (43); increased accumulation in tumor microenvironment (43, 44)